CAS 1173976-40-3

Gefitinib-d3

CAS: 1173976-40-3

Gefitinib-d3

Formula: C₂₂H₂₁ClD₃FN₄O₃

Peso molecolare: 449.92

Ref: 54-DE3258

Gefitinib-D3

CAS: 1173976-40-3

Gefitinib-D3 is the deuterated form of Gefitinib. Gefitinib (T1181) (ZD1839) is a potent, selective, and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. It selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and blocks EGFR autophosphorylation in EGF-stimulated tumor cells. Additionally, Gefitinib (T1181) can induce autophagy (autophagy) and exhibits antitumor activity.

Formula: C₂₂H₂₄ClFN₄O₃

Colore e forma: Solid

Peso molecolare: 449.92

Ref: TM-TMID-0377

Gefitinib-d3

Prodotto controllato

CAS: 1173976-40-3

Applications Labelled Gefitinib (G304000). Gefitinib is an antineoplastic.
References Anderson, N.G., et al.: Int. J. Cancer, 94, 774 (2001), Hirata, A., et al.: Cancer Res., 62, 2554 (2002), Kris, M.G., et al.: J. Am. Med. Assoc., 290, 2149 (2003), Tamura, K., et al.: Expert Opin. Pharmacother., 6, 985 (2005),

Formula: C₂₂H₂₁D₃ClFN₄O₃

Colore e forma: Neat

Peso molecolare: 449.92

Ref: TR-G304002

Gefitinib-d3

CAS: 1173976-40-3

Gefitinib-d3 is a potent inhibitor of the protein kinase activity of the epidermal growth factor receptor (EGFR). It is used in medicinal chemistry research to study the mechanisms of apoptosis and cell cycle regulation. Gefitinib-d3 inhibits cyclin-dependent kinases, which play a key role in tumor growth and proliferation. This drug has been shown to be effective against several types of human cancer, including leukemia, lung cancer, and breast cancer. It works by blocking the signals that stimulate cell growth and division, leading to the death of cancer cells. Gefitinib-d3 is an important tool for researchers studying the molecular mechanisms underlying cancer development and progression.

Formula: C₂₂H₂₄ClFN₄O₃

Purezza: Min. 95%

Peso molecolare: 449.9 g/mol

Ref: 3D-YWB97640